HER2 Testing in Breast Cancer (Online CE Course)

(based on 15 customer ratings)

Author: Kathryn R. Perkinson, BS, HTL(ASCP)
Reviewers: Jim Burchette, HT(ASCP); Donna Hedger, BS, HT(ASCP)

HER2/neu is a useful tumor marker for therapeutic decision making in patients with breast cancer. This course includes a review current breast cancer statistics, a comparison of methods used for HER2/neu testing, proper interpretation of HER2/neu fluorescence in situ hybridization (FISH), and the College of American Pathologists (CAP) guidelines for HER2/neu FISH testing.

See all available courses »

Continuing Education Credits

P.A.C.E.® Contact Hours (acceptable for AMT, ASCP, and state recertification): 2 hour(s)
Course number 578-076-16, approved through 8/31/2018
Course number 20-576308, approved through 9/1/2018

Objectives

  • Review current breast cancer statistics.
  • Compare methods for HER2 testing.
  • Understand the College of American Pathologists (CAP) guidelines for HER2 fluorescence in situ hybridization (FISH) testing.
  • Outline the method for HER2 FISH assay.
  • Demonstrate proper interpretation of HER2 FISH assay.

Customer Ratings

(based on 15 customer ratings)

Course Outline

Click on the links below to preview selected pages from this course.

Additional Information

Level of instruction: Beginning to intermediate
Intended audience:  Clinical laboratory histotechnologists, histotechnicians, and other medical laboratory personnel who have an interest in this subject matter. This course is also appropriate for histology and clinical laboratory science students, pathology residents, and practicing pathologists.  
Author information: Kathryn R. Perkinson, BS, HTL(ASCP) has been the manager of the Molecular Pathology Department of Duke University Health System in Durham, North Carolina since 1998.  She holds a  Bachelor of Science degree in biochemistry from North Carolina State University. Kathryn has over 25 years of experience in molecular biology in both the research and clinical healthcare fields at Duke University. The Molecular Pathology Department, under her leadership, has tripled in size over the past 15 years. 
Reviewer information: Jim Burchette, HT(ASCP) is retired from Duke University Medical Center, Durham, North Carolina as an Immunopathology Analytical Specialist in Molecular Pathology. He has over 38 years of experience in surgical pathology histotechnology with 33 years of immunopathology specialty. Jim has authored numerous peer-reviewed publications, (www.pubmed.com; search burchette j), two book chapters, and many abstracts, posters, and technical acknowledgments in peer reviewed scientific articles. Jim served as a consultant for Triangle Biomedical Sciences (TBS), Dako North America, Leica Microsystems, and Polysciences.
Donna M. Hedger, BS, HT(ASCP) is the Pathology Manager at Gwinnett Hospital System in Lawrenceville, Georgia. She graduated from Georgia Southern University with a Bachelor of Science in Biology. She is a certified histotechnician.
Course description: HER2 is a useful tumor marker for therapeutic decision making in patients with breast cancer. This course includes a review of current breast cancer statistics and compares various methods for HER2 testing. Information is based on the current ASCO/CAP HER2 Test Guideline Recommendations (2013). 

How to Subscribe
Histology CE Package$65 Add to cart
Individual course$20 Add to cart


her2 pg 61


her2 pg 62


her2 pg 64


her2 slide 22


HER2 testing timeline